A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

The Journal of Endocrinology
Hongbin LiuRichard W Simpson

Abstract

Glucagon-like peptide-1 (GLP-1) administration attenuates endothelial cell dysfunction in diabetic patients and inhibits tumour necrosis factor alpha (TNF)-mediated plasminogen activator inhibitor type-1 (PAI-1) induction in human vascular endothelial cells. The short half-life of GLP-1 mediated via degradation by the enzyme dipeptidyl peptidase 4 mandates the clinical use of long-acting GLP-1 analogues. The effects of a long-acting GLP-1 analogue on PAI-1 and vascular adhesion molecule expression in vascular endothelial cells are unknown. In this report, we demonstrate for the first time that the treatment with liraglutide, a long-acting GLP-1 analogue, inhibited TNF or hyperglycaemia-mediated induction of PAI-1, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 mRNA and protein expression in a human vascular endothelial cell line. In addition, treatment attenuated TNF- or hyperglycaemia-mediated induction of the orphan nuclear receptor Nur77 mRNA expression. Taken together, these observations indicate that liraglutide inhibits TNF- or glucose-mediated induction of PAI-1 and vascular adhesion molecule expression, and this effect may involve the modulation of NUR77. These effects suggest that liraglutide m...Continue Reading

Associated Clinical Trials

Citations

May 15, 2010·Herz·Baptist Gallwitz
Dec 21, 2010·Current Atherosclerosis Reports·Daniel Addison, David Aguilar
Apr 13, 2010·Diabetes, Obesity & Metabolism·Kevin Niswender
Jan 6, 2011·Diabetes, Obesity & Metabolism·P AnagnostisD P Mikhailidis
Aug 31, 2013·Diabetology & Metabolic Syndrome·Asfandyar Sheikh
Feb 11, 2012·Endocrine Reviews·John R Ussher, Daniel J Drucker
Feb 1, 2011·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Xie Xiao-YunXie Yan-Hong
Jan 1, 2010·The Review of Diabetic Studies : RDS·Baptist Gallwitz
Jan 21, 2012·The Review of Diabetic Studies : RDS·Michael Lehrke, Nikolaus Marx
Apr 3, 2010·Patient Preference and Adherence·Mahamood Edavalath, Jeffrey W Stephens
Jun 16, 2012·Indian Journal of Endocrinology and Metabolism·Vishal Gupta
Aug 24, 2013·Journal of Atherosclerosis and Thrombosis·Naoto KatakamiUNKNOWN Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis Trial
Mar 31, 2012·ISRN Endocrinology·Ida KinalskaLukasz Hak
Mar 21, 2012·Herz·M Lehrke, N Marx
Dec 15, 2010·Expert Opinion on Pharmacotherapy·Mansur Shomali
Mar 24, 2012·Current Medical Research and Opinion·Edoardo Mannucci, Ilaria Dicembrini
Jan 20, 2016·Current Atherosclerosis Reports·Ashish SarrajuJoshua W Knowles
Oct 25, 2012·The American Journal of Cardiology·Saurabh SanonRobert Chilton
Jan 11, 2011·Biochemical and Biophysical Research Communications·Hiromasa GotoHirotaka Watada
Oct 24, 2014·Cardiovascular Diabetology·Francisco Kerr Saraiva, Andrei C Sposito
Feb 1, 2012·Diabetic Medicine : a Journal of the British Diabetic Association·T ForstA Pfützner
Mar 18, 2013·Journal of Diabetes Investigation·Yutaka Seino, Daisuke Yabe
May 7, 2011·Journal of Clinical Pharmacy and Therapeutics·Gina J Ryan, Yolanda Hardy
Jul 20, 2013·Cardiovascular Therapeutics·Daniel Lorber
Jan 6, 2015·Microcirculation : the Official Journal of the Microcirculatory Society, Inc·Patricia KellyChristopher A Mitchell
Oct 11, 2014·Mind, Brain and Education : the Official Journal of the International Mind, Brain, and Education Society·Alison L MillerJulie C Lumeng
Apr 26, 2016·Mediators of Inflammation·Young-Sun Lee, Hee-Sook Jun
Mar 25, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·W David Strain, Christine Smith
Apr 2, 2015·Basic & Clinical Pharmacology & Toxicology·Linnéa Eriksson, Thomas Nyström
Jun 13, 2015·European Heart Journal·Ele Ferrannini, Ralph A DeFronzo
Apr 27, 2013·Journal of Diabetes and Its Complications·Akira Mima

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Cell Adhesion Molecules in AS

Cell adhesion molecules expressed on the vascular endothelium and circulating leukocytes in response to inflammatory stimuli are implicated in atherosclerosis. Here is the latest research.